• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>ICO

ICO

  1. Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

    Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

  2. Immune Pharmaceuticals and STC Biologics announce strategic partnership to accelerate the development of NanomAbs®

    Immune Pharmaceuticals and STC Biologics announce strategic partnership to accelerate the development of NanomAbs®

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.